Work

EPZ020411, a PRMT6 inhibitor, suppresses colorectal cancer cell proliferation, migration, and invasion through targeting the TGM2/MAPK axis

Year: 2026
Type: article
Abstract: BACKGROUND Colorectal cancer (CRC) remains a highly fatal cancer worldwide, while metastasis is the main challenge in clinical treatment. Protein arginine methyltransferase 6 (PRMT6), a type I PRMT family member, catalyzes asymmetric methylation of arginine residues and contributes to tumor cell proliferation, invasion, metastasis and chemoresistance by both epigenetic and post-translational mechanisms. Notably, PRMT6 is overexpressed in CRC tissues and is associated with a poor survival outcome for patients. However, its targeted therapy and related mechanisms remain unclear. AIM To investigate the antitumor activity and molecular mechanisms of EPZ020411 in CRC HCT116 and CACO-2 cells. METHODS Human CRC cell lines (HCT116 and CACO-2) were treated with EPZ020411, and cell proliferation, migration and invasion were evaluated by CCK-8, EdU, colony formation, wound healing and Transwell assays. RNA sequencing was performed to screen differentially expressed genes, and the results were validated by reverse transcription-quantitative polymerase chain reaction and western blotting. To assess the functional role of transglutaminase 2 (TGM2), we generated a TGM2 over-expression model. The antitumor efficacy in vivo was evaluated using the xenograft mouse model, and tumor growth, histology and immunohistochemistry were performed. RESULTS EPZ020411 inhibited CRC cell proliferation, migration, and invasion dose-dependently. IC50 values of EPZ020411 in HCT116 and CACO-2 cells at 48 hours were 126 μmol/L and 106 μmol/L. At 24 μmol/L, colony formation decreased by 32% and 50%, migration by ~62% in both lines, and invasion by 64% and 45%, respectively. Transcriptomic analysis revealed marked downregulation of TGM2, which was confirmed at both mRNA and protein levels. Mechanistically, EPZ020411 reduced phosphorylation of JNK and p38, indicating inactivation of the mitogen-activated protein kinases (MAPK) signaling pathway. Functional rescue experiments demonstrated that TGM2 overexpression partially reversed the inhibitory effects of EPZ020411. In vivo , EPZ020411 effectively suppressed tumor growth (45.1% inhibition at 10 mg/kg) without toxicity and reduced TGM2 expression in tumor tissues. CONCLUSION EPZ020411 inhibits CRC in vitro and in vivo via TGM2/MAPK, linking PRMT6-TGM2-MAPK, and suggesting PRMT6 as a potential therapeutic target.
Language: English
Open Access status: diamond
OpenAlex ID: W7204197476
FWCI:
Cites: 24
Cited by:
Related to: 10